Terminated Trial Leaves Questions Open on Adhansia XR Duration vs Concerta
A Phase 4 real-world study comparing extended-release methylphenidate formulations for ADHD was terminated before yielding conclusions.
Summary
This Phase 4 clinical trial set out to evaluate how long Adhansia XR (an extended-release methylphenidate formulation) remained effective in real-world ADHD treatment settings, and whether it outperformed Concerta over time. The study planned to assess effectiveness at two months post-initiation and track outcomes across both treatment arms. However, the trial was terminated before completion, leaving its primary questions unanswered. Sponsored by Purdue Pharma LP, the study reflected growing interest in real-world evidence to supplement controlled trial data. Without published results, clinicians cannot draw conclusions about comparative duration of effect between these two commonly prescribed stimulant medications. The termination underscores a broader challenge in post-market surveillance: industry-sponsored real-world studies are vulnerable to early discontinuation for reasons that may include commercial, regulatory, or logistical factors.
Detailed Summary
Real-world evidence studies are increasingly valued in clinical pharmacology because they capture how treatments perform outside the controlled conditions of randomized trials. For ADHD — one of the most prevalent neurodevelopmental conditions — understanding the duration of effect of stimulant medications in everyday practice is clinically meaningful, affecting dosing schedules, patient adherence, and quality of life.
This Phase 4 study was designed to investigate the real-world effectiveness of Adhansia XR, an extended-release methylphenidate formulation, in patients with Attention-Deficit/Hyperactivity Disorder. The study aimed to assess effectiveness at two months post-initiation and to compare outcomes longitudinally against an active comparator, Concerta — another extended-release methylphenidate product.
The trial was terminated before data collection or analysis could be completed. No results are publicly available, meaning the core research questions — whether Adhansia XR maintains effectiveness over time and how it compares to Concerta in real-world settings — remain unanswered. The registry entry does not specify a reason for termination.
The implications of a terminated trial are significant. Clinicians prescribing Adhansia XR must rely on prior approval-basis data rather than longer-term real-world effectiveness data. Patients and providers choosing between extended-release methylphenidate formulations lack comparative durability evidence that this study could have provided.
The trial's early termination also highlights a broader concern about the completeness of the post-market evidence base for commonly prescribed ADHD medications. Regulatory bodies and independent researchers may need to fill this evidence gap through alternative study designs or meta-analyses of existing formulation data.
Key Findings
- Trial was terminated before completion; no efficacy or safety results are available.
- Study intended to compare Adhansia XR vs Concerta (active comparator) for real-world duration of effect.
- Primary effectiveness endpoint was set at two months post-initiation.
- Termination leaves a gap in post-market real-world evidence for extended-release methylphenidate.
- Sponsor was Purdue Pharma LP; the registry entry does not specify a reason for termination.
Methodology
This was a Phase 4 study comparing Adhansia XR against an active comparator (Concerta) in patients with ADHD, with an effectiveness assessment planned at two months post-initiation. The study was sponsored by Purdue Pharma LP and terminated prior to completion. No methodology details beyond the registry abstract are publicly available.
Study Limitations
The trial was terminated before yielding any results, rendering the study uninformative for clinical decision-making. This summary is based on the registry abstract only, as full protocol and results data are unavailable. The reason for termination is not specified in the available record, limiting interpretation of the discontinuation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.